Scholarlink

Purpose <p>Proteinuria is a key predictor of kidney failure in Immunoglobulin A nephropathy (IgAN) patients, but few real-world studies establishing this association have been conducted in the United States (US). This study evaluated the association between time-averaged proteinuria (TA-P) and risk of kidney failure in patients with IgAN in the US, including TA-P levels of &lt; 0.5&#xa0;g/day and below.</p> Methods <p>This retrospective cohort study used integrated administrative claims from the Komodo Research Data and electronic medical record data from Norstella (January 2016–2026). Adults (≥ 18 years) with IgAN diagnosis, ≥ 3 proteinuria measurements, and no kidney failure before the index date (the day after the third proteinuria measurement) were included. TA-P was calculated as the area under the curve of serial proteinuria measurements divided by the duration of observation. Primary TA-P categories were &lt; 0.5, 0.5-1.0, 1.0-1.5, and ≥ 1.5&#xa0;g/day; additional analyses used a more granular stratification of TA-P &lt; 0.5&#xa0;g/day (&lt; 0.3&#xa0;g/day and 0.3–0.5&#xa0;g/day). The composite study outcome was kidney failure (chronic kidney disease stage 5, sustained eGFR &lt; 15 mL/min/1.73&#xa0;m<sup>2</sup>, dialysis, or kidney transplantation). Associations between TA-P and kidney failure were assessed using Cox proportional hazards models adjusted for baseline characteristics such as demographics, race/ethnicity, hypertension, diabetes, hematuria, and eGFR.</p> Results <p>A total of 1820 patients with IgAN were included in the study (median age 46.8 years; 51.4% male). The mean follow-up was 33.2 months with a maximum follow-up of 108 months. Compared with TA-<i>P</i> &lt; 0.5&#xa0;g/day, adjusted hazard ratios (HRs) for kidney failure were 1.83 (95% confidence interval [CI], 1.38–2.41) for TA-P 0.5–1.0&#xa0;g/day; 2.16 (95% CI, 1.44–3.22) for TA-P 1.0–1.5&#xa0;g/day; and 3.14 (95% CI, 2.16–4.56) for TA-P ≥ 1.5&#xa0;g/day. Compared with TA-P &lt; 0.3&#xa0;g/day, adjusted HRs were 1.71 (95% CI, 1.17–2.50) for TA-P 0.3–0.5&#xa0;g/day; 2.17 (95% CI, 1.59–2.95) for TA-P 0.5–1.0&#xa0;g/day; 2.56 (95% CI, 1.67–3.91) for TA-P 1.0–1.5&#xa0;g/day; and 3.71 (95% CI, 2.49–5.52) for TA-P ≥ 1.5&#xa0;g/day.</p> Conclusions <p>Lower TA-P was associated with progressively reduced risk of kidney failure in adults with IgAN in the US. After adjusting for demographics and clinical characteristics, the risk was significantly lower at TA-P &lt; 0.3&#xa0;g/day even when compared with TA-P levels of 0.3–0.5&#xa0;g/day. This underscores the importance of achieving and maintaining proteinuria levels below the threshold of 0.5&#xa0;g/day and ideally &lt; 0.3&#xa0;g/day to delay kidney failure, consistent with KDIGO recommended treatment goals.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Proteinuria and risk of kidney failure in US adults with Immunoglobulin A nephropathy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月27日

查看全文
  • Ankit Shah,
  • Manish Maski,
  • Jiahua Li,
  • Joel Iff,
  • Rajeshwari Nair,
  • Patrick Gagnon-Sanschagrin,
  • Jerome Bedard,
  • Edward Tuttle,
  • Beth Barber

摘要

Purpose

Proteinuria is a key predictor of kidney failure in Immunoglobulin A nephropathy (IgAN) patients, but few real-world studies establishing this association have been conducted in the United States (US). This study evaluated the association between time-averaged proteinuria (TA-P) and risk of kidney failure in patients with IgAN in the US, including TA-P levels of < 0.5 g/day and below.

Methods

This retrospective cohort study used integrated administrative claims from the Komodo Research Data and electronic medical record data from Norstella (January 2016–2026). Adults (≥ 18 years) with IgAN diagnosis, ≥ 3 proteinuria measurements, and no kidney failure before the index date (the day after the third proteinuria measurement) were included. TA-P was calculated as the area under the curve of serial proteinuria measurements divided by the duration of observation. Primary TA-P categories were < 0.5, 0.5-1.0, 1.0-1.5, and ≥ 1.5 g/day; additional analyses used a more granular stratification of TA-P < 0.5 g/day (< 0.3 g/day and 0.3–0.5 g/day). The composite study outcome was kidney failure (chronic kidney disease stage 5, sustained eGFR < 15 mL/min/1.73 m2, dialysis, or kidney transplantation). Associations between TA-P and kidney failure were assessed using Cox proportional hazards models adjusted for baseline characteristics such as demographics, race/ethnicity, hypertension, diabetes, hematuria, and eGFR.

Results

A total of 1820 patients with IgAN were included in the study (median age 46.8 years; 51.4% male). The mean follow-up was 33.2 months with a maximum follow-up of 108 months. Compared with TA-P < 0.5 g/day, adjusted hazard ratios (HRs) for kidney failure were 1.83 (95% confidence interval [CI], 1.38–2.41) for TA-P 0.5–1.0 g/day; 2.16 (95% CI, 1.44–3.22) for TA-P 1.0–1.5 g/day; and 3.14 (95% CI, 2.16–4.56) for TA-P ≥ 1.5 g/day. Compared with TA-P < 0.3 g/day, adjusted HRs were 1.71 (95% CI, 1.17–2.50) for TA-P 0.3–0.5 g/day; 2.17 (95% CI, 1.59–2.95) for TA-P 0.5–1.0 g/day; 2.56 (95% CI, 1.67–3.91) for TA-P 1.0–1.5 g/day; and 3.71 (95% CI, 2.49–5.52) for TA-P ≥ 1.5 g/day.

Conclusions

Lower TA-P was associated with progressively reduced risk of kidney failure in adults with IgAN in the US. After adjusting for demographics and clinical characteristics, the risk was significantly lower at TA-P < 0.3 g/day even when compared with TA-P levels of 0.3–0.5 g/day. This underscores the importance of achieving and maintaining proteinuria levels below the threshold of 0.5 g/day and ideally < 0.3 g/day to delay kidney failure, consistent with KDIGO recommended treatment goals.